

# Coronavirus Disease 2019 Vaccine Tracker (Lexi-Drugs Multinational)

Candidate SARS-CoV-2 Vaccines in Advanced Clinical Trials: Key Aspects							
Compiled by John D. Grabenstein, RPh, PhD		All dates are estimates					
Vaccine Sponsor [with Major Partners]	Univ. of Oxford (Jenner Institute) with AstraZeneca	ModernaTX USA	BioNTech with Pfizer	Johnson & Johnson (Janssen Vaccines)	Novavax	Sanofi Pasteur with GlaxoSmithKline	CureVac
Product Designator	ChAdOx1 or AZD1222	mRNA-1273	BNT162-b2	Ad26.COVS-2 or S.PP	NVX-CoV2373	TBA	CVnCoV
Vaccine Type	Adenovirus vector	mRNA	mRNA	Adenovirus vector	Subunit protein	Subunit protein	mRNA
Product Features	Chimpanzee adenovirus type 63 vector	Within lipid nanoparticle dispersion	Within lipid nanoparticle dispersion	Human adenovirus type 26 vector	Adjuvanted with Matrix-M	Adjuvanted with AS03 or AF03	Adjuvanted with AS03
Production Medium (origin)	HEK-293A (human embryo)	Cell free	Cell free	PER.C6 (human embryo)	Baculovirus/Sf9 (insect)	Baculovirus/Sf9 (insect)	Cell free
Route	IM	IM	IM	IM	IM	IM	IM
Dosing Regimen	Single dose or Days 0 + 28 to 42	Days 0 + 28	Days 0 + 21	Single dose or Days 0 + 56	Days 0 + 21	Days 0 + 21	Days 0 + 28
Expected Dose	5x10 <sup>10</sup> viral particles	100 mcg	30 mcg	1x10 <sup>11</sup> viral particles	5 or 25 mcg, TBD	5 or 15 mcg, TBD	6 or 8 mcg, TBD
Expected Packaging	TBA	Frozen liquid. 10-dose vial, preservative-free	Frozen liquid. 5-dose vial, preservative-free	TBA	TBA	TBA	TBA
Expected Storage & Handling Conditions	Refrigerate @ 2°C to 8°C	Ship @ -20°C. Refrigerate @ 2°C to 8°C NMT 1 week	Ship and store on dry ice. Refrigerate @ 2°C to 8°C NMT 1 day. After diluting, use within 6 hours	Refrigerate @ 2°C to 8°C	Refrigerate @ 2°C to 8°C	Refrigerate @ 2°C to 8°C. Before injection, mix antigen with adjuvant	TBA
Clinical Trial Status	Phase 2/3	Phase 3	Phase 3	Phase 1	Phase 2	Phase 1	Phase 2
Date Data Sufficient for EUA	2020 Sep?	2020 Oct?	2020 Oct?	2021 Jan?	2021 Jan?	2021 Jan?	2021 Jan?
Goal Date to File for Licensure	2020 Oct?	2020 Nov?	2020 Dec?	2021 Mar?	2021 Apr?	2021 Jun?	2021 Jun?
US Gov't Contracts, 2020-21 (doses)	300 million	100 million	100 million	100 million	100 million	100 million	
Clinicaltrials.gov Numbers	NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04536051	NCT04283461, NCT04405076, NCT04470427	NCT04368728, NCT04380701, NCT04523571	NCT04436276, NCT04505722, NCT04509947	NCT04368988	NCT04537208	NCT04449276, NCT04515147
Ages Studied to Date (y)	18 to 55, 5 to 12	≥18	18 to 85	≥18	18 to 59	≥18	≥18
Evidence in Non-Human Primates	Graham 2020; van Doremalen 2020	Corbett 2020	Sahin 2020	Mercado 2020; Yu 2020	Guebre-Xabier 2020; Tian 2020		
Evidence in Humans	Folegatti 2020	Jackson 2020	Mulligan 2020; Walsh 2020		Keech 2020		
Analogous Licensed Vaccines	No other adenovirus type-63 based vaccine	No other licensed mRNA vaccine	No other licensed mRNA vaccine	Adenovirus type-26 EU- registered Ebola vaccine component <i>Zabdeno</i> (Janssen, JNJ)	Influenza hemagglutinin vaccine ( <i>FluBlok</i> , Sanofi), with NVX-CoV2373 adding an adjuvant	Influenza hemagglutinin vaccine ( <i>FluBlok</i> , Sanofi), with this candidate adding an adjuvant	No other licensed mRNA vaccine

**Abbreviations & Acronyms:** EUA (Emergency Use Authorization); mRNA (messenger ribonucleic acid); NMT (not more than); Sf9 (*Spodoptera frugiperda*); TBA (to be announced); TBD (to be determined)

Last updated: 9/4/2020

## CLINICAL TRIALS:

<https://clinicaltrials.gov/ct2/show/NCT04324606>

<https://clinicaltrials.gov/ct2/show/NCT04400838>

<https://clinicaltrials.gov/ct2/show/NCT04444674>

<https://clinicaltrials.gov/ct2/show/NCT04516746>

<https://clinicaltrials.gov/ct2/show/NCT04283461>

<https://clinicaltrials.gov/ct2/show/NCT04405076>

<https://clinicaltrials.gov/ct2/show/NCT04470427>

<https://clinicaltrials.gov/ct2/show/NCT04368728>

<https://clinicaltrials.gov/ct2/show/NCT04380701>

<https://clinicaltrials.gov/ct2/show/NCT04523571>

<https://clinicaltrials.gov/ct2/show/NCT04436276>

<https://clinicaltrials.gov/ct2/show/NCT04505722>

<https://clinicaltrials.gov/ct2/show/NCT04509947>

<https://clinicaltrials.gov/ct2/show/NCT04368988>

<https://clinicaltrials.gov/ct2/show/NCT04449276>

<https://clinicaltrials.gov/ct2/show/NCT04515147>

## REFERENCES:

Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates [published online July 28, 2020]. *N Engl J Med*. doi:10.1056/NEJMoa2024671. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa2024671>[PubMed 32722908]

Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):467-478. doi:10.1016/S0140-6736(20)31604-4. Available at [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31604-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext)[PubMed 32702298]

Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science*. 2020;369(6499):77-81. doi:10.1126/science.abc1932. Available at <https://science.sciencemag.org/content/369/6499/77.full>[PubMed 32376603]

Graham SP, McLean RK, Spencer AJ, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. *NPJ Vaccines*. 2020;5:69. doi:10.1038/s41541-020-00221-3. Available at <https://www.nature.com/articles/s41541-020-00221-3>[PubMed 32793398]

Guebre-Xabier M, Patel N, Tian J-H, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge [published online August 19, 2020]. *bioRxiv*. Available at <https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1.full.pdf>

- Jackson LA, Anderson EJ, Roupael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report [published online July 14, 2020]. *N Engl J Med*. doi:10.1056/NEJMoa2022483. Available at <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483>[PubMed 32663912]
- Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N Engl J Med*. 2020. Available at [https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured\\_coronavirus](https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_coronavirus)
- Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques [published online July 30, 2020]. *Nature*. doi:10.1038/s41586-020-2607-z. Available at <https://www.nature.com/articles/s41586-020-2607-z>[PubMed 32731257]
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults [published online August 12, 2020]. *Nature*. doi:10.1038/s41586-020-2639-4. Available at <https://www.nature.com/articles/s41586-020-2639-4>[PubMed 32785213]
- Sahin U, Muik A, Derhovanessian E, et al. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine [published online July 20, 2020]. *medRxiv*. Available at <https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf>
- Tian J-H, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice [published online June 30, 2020]. *bioRxiv*. Available at <https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1.full.pdf>
- van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Preprint [published online May 13, 2020]. *bioRxiv*. doi:10.1101/2020.05.13.093195. Available at <https://doi.org/10.1038/s41586-020-2608-y>[PubMed 32511340]
- Vogel AB, Kanevsky I, Che Y, et al. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates [published online September 8, 2020]. *bioRxiv*. Available at <https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1.full.pdf>
- Walsh EE, Frenck R, Falsey AR, et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Preprint [published online August 20, 2020]. *medRxiv*. doi:10.1101/2020.08.17.20176651 Available at <https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1.full.pdf>[PubMed 32839784]
- Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. *Cell*. 2020;182(3):713-721. doi:10.1016/j.cell.2020.06.008. Available at [https://www.cell.com/cell/fulltext/S0092-8674\(20\)30695-4?\\_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420306954%3Fshowall%3Dtrue](https://www.cell.com/cell/fulltext/S0092-8674(20)30695-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420306954%3Fshowall%3Dtrue)[PubMed 32778225]
- Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials [published online August 13, 2020]. *JAMA*. 2020;e2015543. doi:10.1001/jama.2020.15543[PubMed 32789505]
- Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*. 2020;369(6505):806-811. doi:10.1126/science.abc6284. Available at <https://science.sciencemag.org/content/369/6505/806.full>[PubMed 32434945]
- Zhang Y, Zeng G, Pan H, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial [published online August 10, 2020]. *medRxiv*. Available at <https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1>

Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;396(10249):479-488. doi:10.1016/S0140-6736(20)31605-6. Available at [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31605-6/fulltext\[PubMed 32702299\]](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext[PubMed 32702299])

Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet*. 2020;395(10240):1845-1854. doi:10.1016/S0140-6736(20)31208-3. Available at [https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931208-3\[PubMed 32450106\]](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931208-3[PubMed 32450106])

## RESOURCE DOCUMENTS:

Biomedical Advanced Research & Development Authority (BARDA): Award list: <https://medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx>

Coalition for Epidemic Preparedness Innovations (CEPI): <https://cepi.net/news/>

Food & Drug Administration, Emergency Use Authorizations (EUA): <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>

Food & Drug Administration, Fast Track & Similar Designations: <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review>

 COVID 19 Evidence

## REFERENCES:

Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):467-478. doi:10.1016/S0140-6736(20)31604-4. Available at [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31604-4/fulltext\[PubMed 32702298\]](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext[PubMed 32702298])

Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 – preliminary report [published online July 14, 2020]. *N Engl J Med*. doi:10.1056/NEJMoa2022483. Available at <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483>, [https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl\\_file/nejmoa2022483\\_appendix.pdf\[PubMed 32663912\]](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf[PubMed 32663912])

Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine [published online September 2, 2020]. *N Engl J Med*. doi:10.1056/NEJMoa2026920. Available at [https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured\\_coronavirus\[PubMed 32877576\]](https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_coronavirus[PubMed 32877576])

Miller JM, Moderna, et al. ACIP Presentation: mRNA-1273 clinical development program. By webinar, August 26, 2020. Available at <https://investors.modernatx.com/static-files/34f97bb2-d89a-45e4-a770-cae0591fa807>

Walsh EE, Frenck R, Falsey AR, et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Preprint. *medRxiv*. 2020;2020.08.17.20176651. doi:10.1101/2020.08.17.20176651. Available at [https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1.full.pdf\[PubMed 32839784\]](https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1.full.pdf[PubMed 32839784])

Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials [published online August 13, 2020]. *JAMA*. 2020;e2015543. doi:10.1001/jama.2020.15543[PubMed 32789505]

Zhang Y, Zeng G, Pan H, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial [published online August 10, 2020]. *medRxiv*. Available at <https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1>

Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;396(10249):479-488. doi:10.1016/S0140-6736(20)31605-6. Available at [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31605-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext)[PubMed 32702299]

Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet*. 2020;395(10240):1845-1854. doi:10.1016/S0140-6736(20)31208-3. Available at <https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931208-3>[PubMed 32450106]

## Applies to

Coronavirus Vaccine; COVID-19; COVID-19 Vaccine Tracker; COVID19; COVID19 Vaccine Tracker; SARS-CoV-2 Vaccine

Last Updated 9/15/20